Skip to content

PPHVanEck Pharmaceutical ETF

Grow my money14y track recordRanked #409 of 2,992 in this goal

Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.

By VanEck · Launched 2011

Annual Cost

0.36%

#1,773 of 5,854 · low cost

Fund Size

$879M

#1,202 of 5,854 · large

Return (1Y)Goal

+31.6%

Track Record

14 years

#933 of 5,854 · established

Performance

Total-return NAV · USD
Growth of $10,000
$12,522+25.2%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Cap

Multi cap

Strategy

Index tracking

Focus

Pharmaceuticals

Index tracked

MVIS US Listed Pharmaceutical 25 Index

What it actually holds

By weight

Concentration

Top 10 holdings = 71.8% of fundconcentrated

Eli Lilly & Co
18.7%
Novartis AG
10.8%
Merck & Co Inc
9.7%
Pfizer Inc
5.2%
Novo Nordisk A/S
4.8%
Sanofi SA
4.7%
Bristol-Myers Squibb Co
4.6%
GSK PLC
4.6%
AstraZeneca PLC
4.4%
Johnson & Johnson
4.3%

Asset allocation

Stocks
99.9%
Cash
0.1%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
18.2%Moderate

Year-on-year price swings

Max drawdown
-29.7%Moderate

Worst peak-to-trough loss

Sharpe (3Y)
0.64Decent risk-adjusted returns
Sortino (3Y)
0.94Moderate downside risk

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.
Strategy
Uses a passive investment approach to replicate the Pharmaceutical Index by investing at least 80% of total assets in common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry, including medium-cap companies. Concentrates investments in the pharmaceutical sector to match the index's composition.
Inception date
December 20, 2011
Fund family
VanEck

What's next?

You've looked at PPH. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

Data updated on 2026-08-03